IMR Press / EJGO / Volume 31 / Issue 4 / pii/1630985252201-451748818

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy
Show Less
1 Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo (Japan)
Eur. J. Gynaecol. Oncol. 2010, 31(4), 364–368;
Published: 10 August 2010
Abstract

Purpose: At present, it remains unclear whether the third-line chemotherapy has clinical benefit. In this study, we retrospectively evaluated the effect of third-line chemotherapy. Methods: We reviewed the medical records of 40 women with recurrent epithelial ovarian cancer (EOC) who received third-line chemotherapy after platinum/taxan regimens as first line chemotherapy. Results: In the first recurrence, 23 cases were platinum-sensitive and 17 cases were platinum-resistant. The cases for which the treatment-free interval from second-line chemotherapy (TFI) was _ 3 months had a higher non-PD rate than those with TFI < 3 months (86% vs 33%, p = 0.002). In addition, the median overall survival (OS) was longer for TFI _ 3 months than for TFI < 3 months (1195 days vs 235 days, p = 0.004). Finally, TFI was an independent significant prognostic factor by univariate (HR 3.28, p = 0.006) and multivariate (HR 3.21, p = 0.018) proportional hazard tests. Conclusion: TFI from second-line chemotherapy may predict a survival benefit of third-line chemotherapy.
Keywords
Epithelial ovarian cancer
Recurrence
Third-line chemotherapy
Share
Back to top